Literature DB >> 25048571

Heteromerization of GPR55 and cannabinoid CB2 receptors modulates signalling.

N A Balenga1, E Martínez-Pinilla, J Kargl, R Schröder, M Peinhaupt, W Platzer, Z Bálint, M Zamarbide, I G Dopeso-Reyes, A Ricobaraza, J M Pérez-Ortiz, E Kostenis, M Waldhoer, A Heinemann, R Franco.   

Abstract

BACKGROUND AND
PURPOSE: Heteromerization of GPCRs is key to the integration of extracellular signals and the subsequent cell response via several mechanisms including heteromer-selective ligand binding, trafficking and/or downstream signalling. As the lysophosphatidylinositol GPCR 55 (GPR55) has been shown to affect the function of the cannabinoid receptor subtype 2 (CB2 receptor) in human neutrophils, we investigated the possible heteromerization of CB2 receptors with GPR55. EXPERIMENTAL APPROACH: The direct interaction of human GPR55 and CB2 receptors heterologously expressed in HEK293 cells was assessed by co-immunoprecipitation and bioluminescence resonance energy transfer assays. The effect of cross-talk on signalling was investigated at downstream levels by label-free real-time methods (Epic dynamic mass redistribution and CellKey impedance assays), ERK1/2-MAPK activation and gene reporter assays. KEY
RESULTS: GPR55 and CB2 receptors co-localized on the surface of HEK293 cells, co-precipitated in membrane extracts and formed heteromers in living HEK293 cells. Whereas heteromerization led to a reduction in GPR55-mediated activation of transcription factors (nuclear factor of activated T-cells, NF-κB and cAMP response element), ERK1/2-MAPK activation was potentiated in the presence of CB2 receptors. CB2 receptor-mediated signalling was also affected by co-expression with GPR55. Label-free assays confirmed cross-talk between the two receptors. CONCLUSIONS AND IMPLICATIONS: Heteromers, unique signalling units, form in HEK293 cells expressing GPR55 and CB2 receptors. The signalling by agonists of either receptor was governed (i) by the presence or absence of the partner receptors (with the consequent formation of heteromers) and (ii) by the activation state of the partner receptor.
© 2014 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25048571      PMCID: PMC4294047          DOI: 10.1111/bph.12850

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  75 in total

1.  A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers.

Authors:  Maria Waldhoer; Jamie Fong; Robert M Jones; Mary M Lunzer; Shiv K Sharma; Evi Kostenis; Philip S Portoghese; Jennifer L Whistler
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-02       Impact factor: 11.205

2.  Comparing label-free biosensors for pharmacological screening with cell-based functional assays.

Authors:  Matthew F Peters; François Vaillancourt; Madeleine Heroux; Manon Valiquette; Clay W Scott
Journal:  Assay Drug Dev Technol       Date:  2010-04       Impact factor: 1.738

Review 3.  GPR55, a lysophosphatidylinositol receptor with cannabinoid sensitivity?

Authors:  Tapio Nevalainen; Andrew J Irving
Journal:  Curr Top Med Chem       Date:  2010       Impact factor: 3.295

4.  The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints.

Authors:  Robert Fredriksson; Malin C Lagerström; Lars-Gustav Lundin; Helgi B Schiöth
Journal:  Mol Pharmacol       Date:  2003-06       Impact factor: 4.436

5.  The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation.

Authors:  Christopher M Henstridge; Nariman A B Balenga; Lesley A Ford; Ruth A Ross; Maria Waldhoer; Andrew J Irving
Journal:  FASEB J       Date:  2008-08-29       Impact factor: 5.191

6.  Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.

Authors:  C C Felder; K E Joyce; E M Briley; J Mansouri; K Mackie; O Blond; Y Lai; A L Ma; R L Mitchell
Journal:  Mol Pharmacol       Date:  1995-09       Impact factor: 4.436

7.  Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands.

Authors:  Ankur Kapur; Pingwei Zhao; Haleli Sharir; Yushi Bai; Marc G Caron; Larry S Barak; Mary E Abood
Journal:  J Biol Chem       Date:  2009-09-01       Impact factor: 5.157

8.  NGF upregulates the plasminogen activation inhibitor-1 in neurons via the calcineurin/NFAT pathway and the Down syndrome-related proteins DYRK1A and RCAN1 attenuate this effect.

Authors:  Georgios C Stefos; Ulf Soppa; Mara Dierssen; Walter Becker
Journal:  PLoS One       Date:  2013-06-25       Impact factor: 3.240

9.  Lysophosphatidylinositol causes neurite retraction via GPR55, G13 and RhoA in PC12 cells.

Authors:  Yutaro Obara; Sanae Ueno; Yoshimi Yanagihata; Norimichi Nakahata
Journal:  PLoS One       Date:  2011-08-31       Impact factor: 3.240

10.  The Concise Guide to PHARMACOLOGY 2013/14: enzymes.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

View more
  38 in total

1.  Activation of GPR55 increases neural stem cell proliferation and promotes early adult hippocampal neurogenesis.

Authors:  Jeremy D Hill; Viviana Zuluaga-Ramirez; Sachin Gajghate; Malika Winfield; Yuri Persidsky
Journal:  Br J Pharmacol       Date:  2018-07-04       Impact factor: 8.739

2.  Different receptor mechanisms underlying phytocannabinoid- versus synthetic cannabinoid-induced tetrad effects: Opposite roles of CB1 /CB2 versus GPR55 receptors.

Authors:  Xiao-Fei Wang; Ewa Galaj; Guo-Hua Bi; Cindy Zhang; Yi He; Jia Zhan; Michael H Bauman; Eliot L Gardner; Zheng-Xiong Xi
Journal:  Br J Pharmacol       Date:  2020-02-11       Impact factor: 8.739

Review 3.  Pathogenesis of Systemic Sclerosis.

Authors:  Debendra Pattanaik; Monica Brown; Bradley C Postlethwaite; Arnold E Postlethwaite
Journal:  Front Immunol       Date:  2015-06-08       Impact factor: 7.561

Review 4.  New Insights in Cannabinoid Receptor Structure and Signaling.

Authors:  Lingyan Ye; Zheng Cao; Weiwei Wang; Naiming Zhou
Journal:  Curr Mol Pharmacol       Date:  2019       Impact factor: 3.339

5.  Neuronal expression of CB2 cannabinoid receptor mRNAs in the mouse hippocampus.

Authors:  Y Li; J Kim
Journal:  Neuroscience       Date:  2015-10-26       Impact factor: 3.590

6.  Therapeutic targeting of HER2-CB2R heteromers in HER2-positive breast cancer.

Authors:  Sandra Blasco-Benito; Estefanía Moreno; Marta Seijo-Vila; Isabel Tundidor; Clara Andradas; María M Caffarel; Miriam Caro-Villalobos; Leyre Urigüen; Rebeca Diez-Alarcia; Gema Moreno-Bueno; Lucía Hernández; Luis Manso; Patricia Homar-Ruano; Peter J McCormick; Lucka Bibic; Cristina Bernadó-Morales; Joaquín Arribas; Meritxell Canals; Vicent Casadó; Enric I Canela; Manuel Guzmán; Eduardo Pérez-Gómez; Cristina Sánchez
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-07       Impact factor: 11.205

Review 7.  Insights into the effects of the endocannabinoid system in cancer: a review.

Authors:  Ana Isabel Fraguas-Sánchez; Cristina Martín-Sabroso; Ana Isabel Torres-Suárez
Journal:  Br J Pharmacol       Date:  2018-05-22       Impact factor: 8.739

8.  THC Reduces Ki67-Immunoreactive Cells Derived from Human Primary Glioblastoma in a GPR55-Dependent Manner.

Authors:  Marc Richard Kolbe; Tim Hohmann; Urszula Hohmann; Chalid Ghadban; Ken Mackie; Christin Zöller; Julian Prell; Jörg Illert; Christian Strauss; Faramarz Dehghani
Journal:  Cancers (Basel)       Date:  2021-03-03       Impact factor: 6.639

9.  Cannabinoids as anticancer therapeutic agents.

Authors:  Olga Kovalchuk; Igor Kovalchuk
Journal:  Cell Cycle       Date:  2020-04-05       Impact factor: 4.534

10.  The GPR55 antagonist CID16020046 protects against intestinal inflammation.

Authors:  A Stančić; K Jandl; C Hasenöhrl; F Reichmann; G Marsche; R Schuligoi; A Heinemann; M Storr; R Schicho
Journal:  Neurogastroenterol Motil       Date:  2015-07-30       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.